Z88.8 Insurance Policy Changes

ICD-10 Z88.8 is officially defined as "Allergy status to other drugs, medicaments and biological substances." code Z88.8 is referenced in 3 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z88.8 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 6, 2026Medium impact
Pegzilarginase-nbln (Loargys) (CPB 1101)
Aetna's new clinical policy bulletin (CPB 1101, source dated 2026-10-06) sets the criteria for pegzilarginase-nbln (Loargys) on commercial medical plans for arginase 1 deficiency in patients aged 2 to under 32. Precertification is required, the drug must be prescribed by or with a metabolic or enzyme disorder specialist, and Aetna treats all other indications as experimental, investigational or unproven. No effective date is stated in the source, so check current applicability before acting.
Aetna · Identified Aug 16, 2026Medium impact
Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)
Feraheme, Ferrlecit, Injectafer, Monoferric and Venofer are medically necessary only for commercial members who have a contraindication, intolerance or ineffective response to the lower cost alternatives generic ferumoxytol, generic iron sucrose, generic sodium ferric gluconate and INFeD (iron dextran) for the labeled indication. Precertification is required for Feraheme, Ferrlecit, generic sodium ferric gluconate, Injectafer, Monoferric, Venofer and generic iron sucrose in applicable plan designs. Intravenous iron is considered experimental, investigational or unproven for other indications, including acute mountain sickness and anemia of inflammation, and it is contraindicated for genetic hemochromatosis or hemochromatosis secondary to iron overload.
Aetna · Identified Aug 15, 2026Medium impact
Ixabepilone (Ixempra) (CPB 0869, reviewed 2026-04-07)
Aetna covers ixabepilone (Ixempra) for commercial members with breast cancer that meets one of its criteria: HER2-negative locally advanced, recurrent unresectable or metastatic disease as a single agent; HER2-positive recurrent unresectable or metastatic disease with trastuzumab as fourth line therapy and beyond; or metastatic or locally advanced disease in combination with capecitabine after resistance to an anthracycline and a taxane. Continued use is covered when there is no evidence of unacceptable toxicity or disease progression, and use beyond 3 months (12 weeks) is covered for stable disease with tumor size within 25 % of baseline. Ixabepilone is not medically necessary after a severe (CTC grade 3/4) hypersensitivity reaction to medications formulated with Cremophor EL or its derivatives, and all other indications, including cervical, colorectal, endometrial, gastric, lung, ovarian, pancreatic, prostate and uterine cancers, are considered experimental, investigational or unproven.

Watch Z88.8

Get one email when a payer policy names Z88.8, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z88.8?

There are 3 tracked policy changes affecting code Z88.8, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z88.8?

Payers that have issued tracked updates for code Z88.8 include: Aetna.

How do I get notified when code Z88.8 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z88.8. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z88.8?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pegzilarginase-nbln (Loargys) (CPB 1101)

Intravenous Iron Therapy (CPB 0575, reviewed 2026-07-01)

Ixabepilone (Ixempra) (CPB 0869, reviewed 2026-04-07)

What insurance policy changes affect code Z88.8?

Which payers have updated policy for code Z88.8?

How do I get notified when code Z88.8 policy changes?

Why do payers change policies for code Z88.8?